Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionHsbc Holdings Plc
Latest Disclosed Ownership184,222 shares
Latest Disclosed Value $ 24,297,335
Hsbc Holdings Plc reports 169.76% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 30, 2026 - Hsbc Holdings Plc filed a 13F-HR form disclosing ownership of 184,222 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $24,297,335 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 20, 2026 disclosing 68,292 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 169.76% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 184,222 115,930 169.76 24,297 150.90 0.0017
2026-03-20 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 68,292 -115,365 -62.82 9,685 -62.43 0.0005
2026-03-06 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,292 -115,365 -62.82 9,685 -62.43 0.0004
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 183,657 -5,580 -2.95 25,777 8.37 0.0020
2025-08-13 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 189,237 -53,798 -22.14 23,787 -11.53 0.0143
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 243,035 30,681 14.45 26,887 -7.28 0.0166
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 212,354 -10,904 -4.88 28,998 12.92 0.0169
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 223,258 110,185 97.45 25,679 64.85 0.0149
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 113,073 -26,793 -19.16 15,577 -19.21 0.0095
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 139,866 35,910 34.54 19,282 40.60 0.0131
2024-02-12 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 103,956 25,975 33.31 13,715 56.14 0.0120
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 77,981 1,012 1.31 8,784 21.01 0.0091
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 76,969 -37,946 -33.02 7,259 -37.47 0.0074
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 114,915 36,616 46.76 11,609 24.20 0.0139
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 78,299 10,291 15.13 9,346 29.41 0.0107
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,008 9,334 15.91 7,222 26.24 0.0118
2022-08-11 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,674 518 0.89 5,721 4.90 0.0080
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,156 4,781 8.96 5,454 19.84 0.0066
2022-02-11 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 53,375 8,975 20.21 4,551 6.91 0.0042
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 44,400 13,817 45.18 4,257 42.47 0.0043
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,583 20,357 199.07 2,988 200.91 0.0032
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,226 -6,190 -37.71 993 -37.07 0.0012
2021-02-25 2020-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 16,416 1,379 9.17 1,578 8.60 0.0021
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,416 1,379 1,578 374.6752
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,037 -3,540 -19.06 1,453 -35.88 0.0023
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,577 11,975 181.38 2,266 296.15 0.0043
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,602 -8,090 -55.06 572 -63.91 0.0013
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,692 -4,039 -21.56 1,585 -6.05 0.0028
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,731 5,250 38.94 1,687 48.24 0.0031
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,481 3,486 34.88 1,138 29.32 0.0022
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,995 -137,106 -93.21 880 -91.62 0.0016
2019-02-13 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 147,101 131,592 848.49 10,505 451.73 0.0194
2018-11-13 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,509 15,509 1,904 0.0031
2018-05-11 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -5,765 -100.00 0 -100.00
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,765 5,765 447 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.